|drug3452||Traditional Proning Arm Wiki||1.00|
|drug1541||Hydroxychloroquine and Azithromycin Wiki||0.71|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
Prone positioning is one of the few therapies known to improve mortality in ARDS. Traditionally, patients are proned for 16 hours per 24 hour period. Some retrospective data suggests improvement may persist beyond 16 hours. We aim to perform a pilot study comparing traditional prone positioning to prolonged prone positioning in patients with COVID-induced ARDS.
Description: Time spent in the prone positionMeasure: Duration in prone position Time: 96 hours
Description: Change in P:F ratio from immediately prior to initiation of prone positioning to end of study periodMeasure: Change in P:F ratio Time: 96 hours
Description: Change in drive pressure from immediately prior to initiation of prone positioning to end of the study periodMeasure: Change in Drive Pressure Time: 96 hours
Description: Number of unplanned extubationsMeasure: Unplanned extubations Time: 96 hours
Description: Number of pressure ulcersMeasure: Pressure ulcers Time: 96 hours
Description: Number of displaced central venous line or arterial lineMeasure: Line displacement Time: 96 hours
Description: Number of days on mechanical ventilationMeasure: Duration of mechanical ventilation Time: 30 days
Description: MortalityMeasure: Mortality Time: 30 days
Description: New initiation of inhaled pulmonary vasodilators, ECMOMeasure: Rescue Interventions Time: 96 hours
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports